MX2017013028A - Mutantes de region constante (fc) con actividad funcional modificada. - Google Patents
Mutantes de region constante (fc) con actividad funcional modificada.Info
- Publication number
- MX2017013028A MX2017013028A MX2017013028A MX2017013028A MX2017013028A MX 2017013028 A MX2017013028 A MX 2017013028A MX 2017013028 A MX2017013028 A MX 2017013028A MX 2017013028 A MX2017013028 A MX 2017013028A MX 2017013028 A MX2017013028 A MX 2017013028A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- mutation
- functional activity
- mutants
- chosen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/6857—Antibody fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
Abstract
La presente invención se relaciona con un polipéptido que comprende una región Fc mutada y que tiene actividad funcional, mediada por la región Fc, que se modifica en comparación con la de un polipéptido parental, caracterizado porque la región Fc comprende por lo menos una combinación de 2 mutaciones, siendo la combinación seleccionada de entre: (i) una mutación seleccionada entre 326E, 326T, 352L, 378V, 378T, 396L, 397M, 421T, 334N, 334R, 307N y 394P; y (ii) por lo menos una mutación seleccionada de 226Y, 227S, 230S, 231V, 234P, 243I, 243L, 246R, 246E, 247T, 248E, 253F, 254F, 255W, 259A, 261R, 262A, 263A, 266M, 267N, 267G, 274E, 274R, 276S, 278H, 379A, 282A, 283G, 284L, 286I, 286Y, 287T, 288E, 288R, 290E, 298N, 302A, 305A, 307P, 308A, 308I, 308G, 309P, 312G, 315D, 316D, 319H, 320T, 320R, 320M, 322E, 323I, 333G, 339T, 349S, 325S, 334N, 334R, 336T, 340E, 343S, 345G, 349H, 350A, 352S, 359A, 361H, 362R, 363I, 366A, 373D, 375R, 377T, 378V, 378T, 380G, 383R, 385R, 389S, 389T, 392R, 393A, 393I, 394P, 396L, 397I, 397M, 398P, 405V, 405L, 410R, 412M, 414R, 421T, 423L, 423Y, 423S, 423P, 428T, 431V, 431T, 434K, 434S, 435R, 436H, 439R, 440G, 440N, 442F, 442P y 447N, siendo la numeración el índice de la EU o el equivalente de Kabat, y siempre que la mutación (i) no se lleve a cabo sobre el mismo aminoácido que la mutación (ii). La presente invención también se relaciona con el uso de tal polipéptido, con composiciones que lo comprenden y con métodos para preparar tal polipéptido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1554101A FR3035879A1 (fr) | 2015-05-07 | 2015-05-07 | Mutants fc a activite fonctionnelle modifiee |
PCT/FR2016/051068 WO2016177984A1 (fr) | 2015-05-07 | 2016-05-06 | MUTANTS Fc A ACTIVITÉ FONCTIONNELLE MODIFIÉE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017013028A true MX2017013028A (es) | 2017-12-08 |
Family
ID=54151308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017013028A MX2017013028A (es) | 2015-05-07 | 2016-05-06 | Mutantes de region constante (fc) con actividad funcional modificada. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11649271B2 (es) |
EP (1) | EP3292145A1 (es) |
JP (1) | JP6830903B2 (es) |
KR (1) | KR20180004125A (es) |
CN (2) | CN115073604A (es) |
AU (2) | AU2016259124B2 (es) |
BR (1) | BR112017023453A2 (es) |
CA (1) | CA2977010A1 (es) |
FR (1) | FR3035879A1 (es) |
MX (1) | MX2017013028A (es) |
WO (1) | WO2016177984A1 (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3035879A1 (fr) | 2015-05-07 | 2016-11-11 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
FR3038517B1 (fr) * | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
BR112019001989A2 (pt) | 2016-08-02 | 2019-08-20 | Visterra Inc | polipeptídeos projetados e usos dos mesmos |
JP7178342B2 (ja) | 2016-08-12 | 2022-11-25 | ヤンセン バイオテツク,インコーポレーテツド | アゴニズム及びエフェクター機能が増強した改変抗体、及び他のFcドメイン含有分子 |
FR3064007A1 (fr) * | 2017-03-20 | 2018-09-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Anticorps pour le traitement de cancers |
FR3075200B1 (fr) * | 2017-12-15 | 2022-12-23 | Lab Francais Du Fractionnement | Variants avec fragment fc ayant une affinite augmentee pour fcrn et une affinite augmentee pour au moins un recepteur du fragment fc |
US11319355B2 (en) * | 2017-12-19 | 2022-05-03 | Xencor, Inc. | Engineered IL-2 Fc fusion proteins |
EP3805400A4 (en) * | 2018-06-04 | 2022-06-29 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule showing changed half-life in cytoplasm |
AU2019326407A1 (en) * | 2018-08-21 | 2021-02-18 | Bioatla, Inc. | Conditionally active proteins with pH selectivity |
JP2022520978A (ja) * | 2019-02-18 | 2022-04-04 | クーリエ セラピューティクス インコーポレイテッド | オルソポックスウイルス主要組織適合性複合体(mhc)クラスi様タンパク質(omcp)と腫瘍特異的結合パートナーを用いた二重特異性融合タンパク質 |
WO2021211956A1 (en) * | 2020-04-17 | 2021-10-21 | Janssen Biotech, Inc. | Biosynthetic glycoprotein populations |
US20230183353A1 (en) * | 2020-05-21 | 2023-06-15 | Zydus Lifesciences Limited | Fc variant and preparation thereof |
CN113186167B (zh) * | 2021-04-28 | 2021-11-30 | 中国食品药品检定研究院 | 用于测定抗cd20单克隆抗体药物adcp生物学活性的方法 |
KR20240003757A (ko) * | 2022-06-29 | 2024-01-09 | 고려대학교 산학협력단 | FcγRIIa 결합 선택성이 향상된 인간 Fc 변이체 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
FR2816319B1 (fr) | 2000-11-08 | 2004-09-03 | Millegen | Utilisation d'adn polymerase mutagene pour la creation de mutations aleatoires |
US7355008B2 (en) * | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
FR2861080B1 (fr) * | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
EP2233500A1 (en) * | 2009-03-20 | 2010-09-29 | LFB Biotechnologies | Optimized Fc variants |
RU2583298C2 (ru) | 2009-10-07 | 2016-05-10 | Макродженикс, Инк. | ПОЛИПЕПТИДЫ, СОДЕРЖАЩИЕ Fc-УЧАСТОК, КОТОРЫЕ ДЕМОНСТРИРУЮТ ПОВЫШЕННУЮ ЭФФЕКТОРНУЮ ФУНКЦИЮ БЛАГОДАРЯ ИЗМЕНЕНИЯМ СТЕПЕНИ ФУКОЗИЛИРОВАНИЯ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ |
WO2011103584A2 (en) * | 2010-02-19 | 2011-08-25 | Xencor, Inc. | Novel ctla4-ig immunoadhesins |
FR3012453B1 (fr) | 2013-10-31 | 2015-11-13 | Lab Francais Du Fractionnement | Proteine chimerique dans le traitement de l’amylose |
FR3035879A1 (fr) | 2015-05-07 | 2016-11-11 | Lab Francais Du Fractionnement | Mutants fc a activite fonctionnelle modifiee |
-
2015
- 2015-05-07 FR FR1554101A patent/FR3035879A1/fr active Pending
-
2016
- 2016-05-06 KR KR1020177031051A patent/KR20180004125A/ko active IP Right Grant
- 2016-05-06 CN CN202210707722.5A patent/CN115073604A/zh active Pending
- 2016-05-06 EP EP16726133.8A patent/EP3292145A1/fr active Pending
- 2016-05-06 US US15/554,022 patent/US11649271B2/en active Active
- 2016-05-06 BR BR112017023453-0A patent/BR112017023453A2/pt active Search and Examination
- 2016-05-06 MX MX2017013028A patent/MX2017013028A/es unknown
- 2016-05-06 CA CA2977010A patent/CA2977010A1/en active Pending
- 2016-05-06 WO PCT/FR2016/051068 patent/WO2016177984A1/fr active Application Filing
- 2016-05-06 JP JP2017554315A patent/JP6830903B2/ja active Active
- 2016-05-06 CN CN201680025478.7A patent/CN107531794B/zh active Active
- 2016-05-06 AU AU2016259124A patent/AU2016259124B2/en active Active
-
2022
- 2022-09-08 AU AU2022228151A patent/AU2022228151A1/en active Pending
-
2023
- 2023-03-31 US US18/193,830 patent/US20230265155A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230265155A1 (en) | 2023-08-24 |
WO2016177984A1 (fr) | 2016-11-10 |
JP6830903B2 (ja) | 2021-02-17 |
CN107531794B (zh) | 2022-07-12 |
AU2016259124B2 (en) | 2022-06-16 |
KR20180004125A (ko) | 2018-01-10 |
US20180030111A1 (en) | 2018-02-01 |
EP3292145A1 (fr) | 2018-03-14 |
CN107531794A (zh) | 2018-01-02 |
AU2022228151A1 (en) | 2022-09-29 |
AU2016259124A1 (en) | 2017-08-31 |
CN115073604A (zh) | 2022-09-20 |
BR112017023453A2 (pt) | 2018-07-31 |
CA2977010A1 (en) | 2016-11-10 |
JP2018515446A (ja) | 2018-06-14 |
US11649271B2 (en) | 2023-05-16 |
FR3035879A1 (fr) | 2016-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017013028A (es) | Mutantes de region constante (fc) con actividad funcional modificada. | |
IL254919B (en) | Polypeptide-based transport means for improving the transport efficiency of polypeptide cargoes into the cytosol of eukaryotic target cells, uses thereof, methods and kits related thereto | |
PH12016501623A1 (en) | Compositions for the inactivation of virus replication and methods of making and using the same | |
MX2021008318A (es) | Nuevos polipeptidos de union especifica y usos de los mismos. | |
MX354049B (es) | Método rápido para la clonación y expresión de segmentos génicos de regiones variables de anticuerpos cognados. | |
MY177826A (en) | Steel for nitrocarburizing and nitrocarburized component using the steel as material | |
EA201890756A1 (ru) | Антитела, которые специфически связываются с tl1a | |
AU2015348922A8 (en) | Codon optimized polynucleotide for high level expression of CRM197 | |
MX2018010446A (es) | Lamina de acero de alta resistencia y metodo de fabricacion de la misma. | |
PH12016501579A1 (en) | Novel anti-presepsin antibody | |
UA113909C2 (xx) | Заповнювач, що містить титан, спосіб його виготовлення та його застосування | |
AU2015344324A8 (en) | Endoxylanase mutant, enzyme composition for biomass decomposition, and method for producing sugar solution | |
CN104445948A (zh) | 开式搪玻璃蒸馏罐 | |
MX2018004174A (es) | Control biologico de virus vegetales. | |
MY188494A (en) | High-growth enterovirus 71 strains and vaccines | |
WO2015127365A3 (en) | Calcium-independent sortase a mutants | |
Fedorova et al. | Dependence of the combustion heat of coal on its chemical composition | |
Mar et al. | Author Correction: Mammal diversity influences the carbon cycle through trophic interactions in the Amazon | |
BRICE et al. | Process for obtaining a substrate equipped with a coating | |
Goltsova | World hydrogen movement: scientific communities of hydrogen energy and hydrogen material science-historical and modern aspects | |
Capron et al. | Going abroad in search of higher productivity at home | |
Jiang et al. | Construction and expression of prokaryotic expression vector of SLA-2-YTH derived from yantai black pig | |
IL'ICHEVA et al. | Producing of a Recombinant Domain of Telomer-Binding Protein TRF2 and Antibodies to it | |
Petersen et al. | Corrigendum to “What is sustainable intensification: Views from experts”[Land Use Policy 46C (2015) 01–10] | |
吉艺宽 et al. | Prokaryotic expression of main antigen epitope of pseudorabies virus gE gene in Escherichia coli and establishment of indirect ELISA |